shutterstock_138095450

Gilead and Jounce Therapeutics forge immuno-oncology partnership worth a potential $700m+

pharmafile | September 2, 2020 | News story | Research and Development, Sales and Marketing |  Gilead, jounce, oncology, pharma 

Gilead and Jounce Therapeutics have come together in a new immuno-oncology partnership potentially worth over $700 million.

The primary drive of the deal for Gilead is to secure exclusive licensing rights to Jounce’s JTX-1811, a monoclonal antibody which targets the chemokine receptor CCR88 to selectively deplete immunosuppressive tumour-infiltration T regulatory (TITR) cells.

Gilead will make an upfront payment of $85 million in exchange for a $35 million equity stake in Jounce. As part of the deal, Jounce will be eligible for a further $685 million on achievement of clinical, regulatory and commercial milestones, as well as “high single digit to mid-teen royalties” on sales.

The news of the deal sent Jounce’s share price surging by 70%.

Advertisement

Concerning JTX-1811, Jounce will continue to develop the therapy until it secures Investigational New Drug (IND) clearance, currently estimated to be in the first half of next year. From that point, Gilead will take over development as the sole license holder.

“We are very pleased to add, upon closing of the transaction, JTX-1811 to our pipeline of investigational immuno-oncology therapies that have the potential to transform care for patients with cancer,” remarked William A Lee, Gilead’s Executive Vice President of Research. “JTX-1811 is complementary to our other oncology candidates and has the potential to be first in a new class of therapies as a treatment for people with both solid tumours and haematological malignancies.”

Matt Fellows

Related Content

START and Rome cancer institute partner to expand early-phase trial access in Italy

The START Center for Cancer Research is partnering with Rome-based Istituti Fisioterapici Ospitalieri (IFO) to …

Highlighting the value of lab research for healthcare innovation

Diagnostic innovation and patient safety have dominated this year’s healthcare-focussed awards to mark European Laboratory …

Charity commits £800,000 to AI research into late breast cancer recurrence

Breast Cancer Now is investing £800,000 in two research projects using artificial intelligence to investigate …

The Gateway to Local Adoption Series

Latest content